13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001381843
Total reported value
$371.7M
$371.7M
37 檔
23.0%
In Q1 2025, Atle Fund Management AB's U.S. equity holdings reached a combined market value of $371.7M, distributed across 37 disclosed stock positions.
In Q1 2025, Atle Fund Management AB displayed an active expansion posture, initiating 37 new positions and adding to 0 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | Stock-Healthcare | 12.62% | +0.95% | -6.65% | |
| 2 | ABBV | Abbvie Inc | Stock-Healthcare | 8.25% | +1.00% | -1.65% | |
| 3 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 5.96% | -0.90% | EXIT | |
| 4 | BSX | Boston Scientific CORP | Stock-Healthcare | 5.89% | -1.18% | -14.23% | |
| 5 | MRK | Merck & Co. Inc. | Stock-Healthcare | 5.06% | -0.85% | +20.76% | |
| 6 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 5.02% | -0.91% | -8.19% | |
| 7 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 4.88% | -1.05% | +2.48% | |
| 8 | COR | Cencora Inc | Stock-Healthcare | 3.87% | +0.24% | -3.07% | |
| 9 | GILD | Gilead Sciences Inc | Stock-Healthcare | 3.81% | -0.74% | — | |
| 10 | SYK | Stryker CORP | Stock-Healthcare | 3.78% | -0.53% | -10.37% | |
| 11 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 3.71% | +0.77% | +11.98% | |
| 12 | AMGN | Amgen Inc | Stock-Healthcare | 3.66% | -2.81% | EXIT | |
| 13 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 3.36% | -0.41% | — | |
| 14 | ALKS | Alkermes plc | Stock-Healthcare | 3.13% | +0.35% | -19.41% | |
| 15 | ONC | Beone Medicines Ltd-adr | Stock-Other | 3.02% | -1.22% | +130.65% | |
| 16 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 2.31% | -1.34% | +46.89% | |
| 17 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.91% | -0.16% | -12.59% | |
| 18 | UFPT | Ufp Technologies Inc | Stock-Other | 1.89% | — | -8.20% | |
| 19 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 1.87% | +0.21% | +155.28% | |
| 20 | CAH | Cardinal Health Inc | Stock-Healthcare | 1.68% | -0.03% | -9.75% | |
| 21 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 1.54% | +0.15% | -33.79% | |
| 22 | DXCM | Dexcom Inc | Stock-Healthcare | 1.38% | +0.45% | -23.67% | |
| 23 | HRMY | Harmony Biosciences Holdings | Stock-Other | 1.34% | — | -24.23% | |
| 24 | ACLXGBX | Arcellx Inc | Stock-Other | 1.28% | — | +4.99% | |
| 25 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 1.17% | -0.71% | EXIT | |
| 26 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.97% | +0.49% | -22.45% | |
| 27 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 0.97% | — | — | |
| 28 | IRTC | Irhythm Holdings Inc | Stock-Healthcare | 0.95% | -0.29% | — | |
| 29 | SMMT | Summit Therapeutics Inc | Stock-Other | 0.89% | — | +3.85% | |
| 30 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.86% | +0.75% | -11.58% | |
| 31 | BCAX | Bicara Therapeutics Inc | Stock-Other | 0.69% | +0.41% | — | |
| 32 | ✓ | Merus N V | Stock-Other | 0.66% | — | -43.55% | |
| 33 | JANX | Janux Therapeutics Inc | Stock-Other | 0.56% | — | +18.28% | |
| 34 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.39% | — | — | |
| 35 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.33% | — | — | |
| 36 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.23% | — | — | |
| 37 | CABA | Cabaletta Bio Inc | Stock-Other | 0.11% | — | -26.31% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | — | NEW | New buy |
| 2 | ABBV | Abbvie Inc | — | NEW | New buy |
| 3 | UNH | Unitedhealth Group Inc | — | NEW | New buy |
| 4 | BSX | Boston Scientific CORP | — | NEW | New buy |
| 5 | MRK | Merck & Co. Inc. | — | NEW | New buy |
| 6 | TMO | Thermo Fisher Scientific Inc | — | NEW | New buy |
| 7 | VRTX | Vertex Pharmaceuticals Inc | — | NEW | New buy |
| 8 | COR | Cencora Inc | — | NEW | New buy |
| 9 | GILD | Gilead Sciences Inc | — | NEW | New buy |
| 10 | SYK | Stryker CORP | — | NEW | New buy |
| 11 | NBIX | Neurocrine Biosciences Inc | — | NEW | New buy |
| 12 | AMGN | Amgen Inc | — | NEW | New buy |
| 13 | ISRG | Intuitive Surgical Inc | — | NEW | New buy |
| 14 | ALKS | Alkermes plc | — | NEW | New buy |
| 15 | ONC | Beone Medicines Ltd-adr | — | NEW | New buy |
| 16 | BBIO | Bridgebio Pharma Inc | — | NEW | New buy |
| 17 | EW | Edwards Lifesciences CORP | — | NEW | New buy |
| 18 | UFPT | Ufp Technologies Inc | — | NEW | New buy |
| 19 | KRYS | Krystal Biotech Inc | — | NEW | New buy |
| 20 | CAH | Cardinal Health Inc | — | NEW | New buy |
| 21 | MIRM | Mirum Pharmaceuticals Inc | — | NEW | New buy |
| 22 | DXCM | Dexcom Inc | — | NEW | New buy |
| 23 | HRMY | Harmony Biosciences Holdings | — | NEW | New buy |
| 24 | ACLXGBX | Arcellx Inc | — | NEW | New buy |
| 25 | SLNOEUR | Soleno Therapeutics Inc | — | NEW | New buy |
| 26 | NAMS | NewAmsterdam Pharma Company N.V. | — | NEW | New buy |
| 27 | VRNA | Verona Pharma PLC - Adr | — | NEW | New buy |
| 28 | IRTC | Irhythm Holdings Inc | — | NEW | New buy |
| 29 | SMMT | Summit Therapeutics Inc | — | NEW | New buy |
| 30 | RVMD | Revolution Medicines Inc | — | NEW | New buy |
| 31 | BCAX | Bicara Therapeutics Inc | — | NEW | New buy |
| 32 | ✓ | Merus N V | — | NEW | New buy |
| 33 | JANX | Janux Therapeutics Inc | — | NEW | New buy |
| 34 | MREO | Mereo Biopharma Group Pl-adr | — | NEW | New buy |
| 35 | AUTL | Autolus Therapeutics PLC | — | NEW | New buy |
| 36 | CRBP | Corbus Pharmaceuticals Holdi | — | NEW | New buy |
| 37 | CABA | Cabaletta Bio Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Atle Fund Management AB reported a total U.S. public equity portfolio value of $371.7M across 37 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LLY, ABBV, UNH) accounted for 23.0% of total reported equity market value during Q1 2025.
Top New Position Initiated
LLY
市值: $28.6M
During Q1 2025, Atle Fund Management AB's top holdings by market value included LLY (12.6%)、ABBV (8.3%)、UNH (6.0%). The largest single position, LLY, represented 12.6% of total portfolio value.
In Q1 2025, Atle Fund Management AB made 37 total portfolio adjustments, initiating 37 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.